Switching ADHD Stimulants: What Your Prescriber Needs to See
A structured before-and-after report template for switching ADHD stimulants — from Ritalin to Concerta, Concerta to Vyvanse/Elvanse, or any other change.
Get new titration guides by email
Occasional, evidence-based guides on medication tracking and titration — no noise.
Disclaimer: This article provides general educational guidance on switching ADHD stimulants. Every switch should be planned and supervised by your licensed prescriber. Never stop, start, or combine medications without explicit medical direction.
Switching ADHD stimulants is common. The first stimulant you try is not always the right one: side effects may be too strong, the effect curve may not fit your day, or the benefits may plateau below what you need. A switch is not a failure — it's a normal part of titration.
What makes a switch successful is usually not the new medication itself. It's the data you bring to the decision. This guide covers the common reasons to switch, how to compare medications during the transition, and the exact report template that gives your prescriber a clear before-and-after picture.
Why people switch stimulants
Stimulants fall into two main classes: methylphenidate-based (Concerta, Ritalin, Medikinet, Equasym) and amphetamine-based (Vyvanse/Elvanse, Adderall, Dexedrine). About 70–80% of people with ADHD respond to stimulants overall, but response to a specific class or formulation is highly individual [1].
Common reasons for switching include:
| Reason | Typical switch direction | Notes |
|---|---|---|
| Side effects too strong | Higher-peak → smoother formulation | e.g., Ritalin IR → Concerta, or Adderall XR → Vyvanse/Elvanse |
| Effect too short | Short-acting → long-acting | e.g., Ritalin IR → Concerta or Vyvanse/Elvanse |
| Rebound too severe | IR → ER, or one ER → another | Prodrugs like Vyvanse/Elvanse often have the least rebound |
| Appetite/weight loss | Amphetamine → methylphenidate, or dose reduction | Methylphenidate is sometimes tolerated better |
| Sleep disruption | Late-onset formulation → earlier-onset, or timing change | Earlier dosing, booster removal, or class switch |
| Anxiety or jitteriness | Amphetamine → methylphenidate, or add non-stimulant | Individual response varies; some prefer amphetamine |
| Insurance/pharmacy availability | Brand → generic, or one generic → another | Release profiles may differ; log any changes |
A switch within the same class (e.g., Concerta to Ritalin LA) is often about finding a release profile that fits your day. A switch across classes (e.g., methylphenidate to amphetamine) is usually about finding a different side-effect/benefit balance.
The washout question: do you need to stop the old one first?
The short answer is: follow your prescriber's instructions exactly. There is no universal rule.
In practice, many prescribers switch stimulants with little or no washout because the medications are short-acting. For example:
- Ritalin IR to Concerta: often started the next morning
- Concerta to Vyvanse/Elvanse: often started the next morning
- Vyvanse/Elvanse to methylphenidate: often started the next morning
However, some prescribers prefer a brief washout — especially if the previous medication caused insomnia, anxiety, or cardiovascular effects. A 24–48 hour washout lets you observe a clean baseline, but it also means a period of unmedicated functioning, which may not be practical for work or school.
The key is to document the transition. Even a short washout gives you useful baseline data: how do you sleep, eat, and focus without medication? That baseline makes the new medication's effect easier to judge.
What to track during a stimulant switch
A switch is a natural experiment. To make it useful, you need comparable data before and after. Track the same variables on both medications so your prescriber can see what changed.
Core daily metrics
| Metric | How to track | Why it matters |
|---|---|---|
| Dose and time | Exact mg and time taken | Different medications have different timing rules |
| Focus | 1–5 scale at 9 AM, 1 PM, 5 PM | Captures the curve, not just the peak |
| Energy/motivation | 1–5 scale at same times | Distinguishes true benefit from mere activation |
| Irritability/anxiety | 1–5 scale | Side effect that may change with class or dose |
| Appetite | 1–5 scale or meal notes | Very sensitive to medication class and dose |
| Sleep | Onset, total hours, quality | Often the deciding factor in a switch |
| Cardiovascular | Resting HR/BP if you have a cuff | Safety check, especially during dose changes |
| Functional notes | 1–2 sentences | "Completed project X" or "avoided all calls" |
Weekly summary questions
At the end of each week on the new medication, answer these in one sentence each:
- Is my focus better, worse, or the same compared to the previous medication?
- Is my sleep better, worse, or the same?
- Is my appetite better, worse, or the same?
- What is my best time of day on this medication?
- What is my worst time of day on this medication?
- Is the side-effect/benefit trade-off better or worse?
- Do I want to continue this medication, adjust the dose, or try something else?
The stimulant switch report template
Bring this one-page format to your prescriber. It is designed to be scannable in under 60 seconds.
Stimulant Switch Report
Patient name: ___________________
Date range: ___________________
Old medication: ___________________
New medication: ___________________
Dose comparison
| Old medication | New medication | |
|---|---|---|
| Dose | ||
| Time taken | ||
| Days tracked |
Average ratings (1–5 scale)
| Symptom / metric | Old (avg) | New (avg) |
|---|---|---|
| Morning focus | ||
| Afternoon focus | ||
| Evening focus | ||
| Motivation | ||
| Irritability | ||
| Anxiety | ||
| Appetite | ||
| Sleep quality | ||
| Energy rebound/crash |
Functional comparison
| Area | Old medication | New medication |
|---|---|---|
| Work/school productivity | ||
| Home responsibilities | ||
| Social interactions | ||
| Exercise/physical activity |
Side effects checklist
| Side effect | Old | New |
|---|---|---|
| Reduced appetite | □ worse □ same □ better | □ worse □ same □ better |
| Insomnia | □ worse □ same □ better | □ worse □ same □ better |
| Headache | □ worse □ same □ better | □ worse □ same □ better |
| Dry mouth | □ worse □ same □ better | □ worse □ same □ better |
| Anxiety/jitteriness | □ worse □ same □ better | □ worse □ same □ better |
| Heart racing / palpitations | □ worse □ same □ better | □ worse □ same □ better |
| Rebound / crash | □ worse □ same □ better | □ worse □ same □ better |
My recommendation
□ Continue new medication at current dose
□ Increase new medication dose
□ Decrease new medication dose
□ Switch to a different medication
□ Other: ___________________
Questions for my prescriber
This template works because it turns a subjective experience into a structured comparison. Your prescriber can see at a glance whether the switch solved the problem or created new ones.
Special scenarios
Switching from Ritalin IR to Concerta
This is often the first switch for adults newly diagnosed with ADHD. The goal is to move from multiple daily doses to a single morning dose with longer coverage. Expect a flatter curve, less peaks-and-valleys, and possibly less rebound if the timing is right. Some people miss the control of being able to skip a mid-day dose.
Switching from Concerta to Vyvanse/Elvanse
This is a common cross-class switch. The goal is often to reduce rebound, improve duration, or address appetite/anxiety issues. Vyvanse/Elvanse has a smoother curve but a slower onset. Some people feel "less wired" on it; others feel it is less intense and need a higher equivalent dose.
Switching from Vyvanse/Elvanse to methylphenidate
Some adults find Vyvanse/Elvanse too long-lasting or too appetite-suppressing. Methylphenidate often has a shorter duration and may feel "cleaner" for people who metabolize amphetamines poorly. The onset is faster, but the rebound can be sharper.
Switching due to generics or supply issues
If your pharmacy switches you to a different generic, the release profile may differ. Track the same metrics you would for a medication switch. If you notice a meaningful change, tell your prescriber and ask whether a specific formulation can be specified on the prescription.
What your prescriber needs to see
The most useful thing you can bring is not a long narrative. It's a before-and-after comparison. Specifically, your prescriber wants to know:
- Did the switch solve the problem that motivated it?
- Did it create any new problems?
- Is the side-effect/benefit trade-off better?
- Is the dose right, or does it need adjustment?
- Is the timing right?
The report template above gives exactly that. The more structured your data, the less time your prescriber spends reconstructing your experience from memory and the more time they spend on the decision.
Generate your switch report with Titrate
Switching medications is one of the most important times to track. Without data, you and your prescriber are comparing two fuzzy memories. With data, the comparison becomes a clear clinical signal.
Titrate is built for this. Daily check-ins capture dose, timing, effect, and side effects. At the end of a week, Titrate produces a structured comparison report — the same format your prescriber wants to see — showing your old medication and new medication side by side.
→ Start tracking your stimulant switch free ← → See how prescribers view Titrate reports ←
Also see our guides on stimulant titration timelines, Concerta titration, and medication review prep.
FAQ
Q: How long does it take to know if a new stimulant is working? Stimulants work the same day, but judging the right dose and fit usually takes 1–2 weeks. A full comparison between two medications is more reliable after 2–4 weeks of consistent data.
Q: Should I switch classes or just formulations first? Most prescribers try a different formulation within the same class first (e.g., Ritalin IR → Concerta, or Adderall XR → Vyvanse/Elvanse) because the response is more predictable. If two formulations within the same class fail, a cross-class switch is the next step.
Q: Can I keep some of my old medication for emergencies? No. Do not stockpile or self-switch between medications. Combining stimulants or taking extra doses can cause dangerous cardiovascular effects. Follow your prescriber's instructions exactly.
Q: What if the new medication feels worse on day one? Some side effects are strongest on day one and improve over several days. However, severe anxiety, chest pain, palpitations, or a severe headache are not normal — contact your prescriber promptly. For milder side effects, log for a week before deciding.
Q: Do I need to track the same times every day? Yes. Consistency is what makes the data comparable. If you track focus at 9 AM one day and 11 AM the next, the numbers aren't comparable.
Q: What if my old medication was "fine" but not great? That's exactly the situation where a switch helps. "Fine" is not the goal of titration. The goal is the dose and formulation that gives you the best function with the fewest side effects. Data helps you find it.
Q: Can I switch because of cost or insurance? Yes — cost is a legitimate clinical factor. If you need to switch to a generic or a different medication for insurance reasons, use the same tracking approach. If the new option doesn't work as well, the data supports asking for a prior authorization or formulary exception.
Key takeaways
- Switching stimulants is a normal part of ADHD treatment — not a sign that something went wrong.
- The most useful data is a structured before-and-after comparison, not a long description.
- Track the same metrics on both medications so the comparison is valid.
- Common switches include IR to ER, methylphenidate to amphetamine, and brand to generic — each has different expectations.
- Washout is not always needed, but the transition plan should come from your prescriber.
- A one-page report template is usually enough for your prescriber to make a clear decision.
- Titrate automates this report from daily check-ins.
References
- Cortese S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738.
- NICE Guideline NG87 — Attention deficit hyperactivity disorder: diagnosis and management (2018, updated 2019).
- CADDRA — Canadian ADHD Practice Guidelines, 4th edition.
- Faraone SV, et al. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of ADHD. Biol Psychiatry. 2006;59(11):1086-1090.
This article is for educational purposes only. It does not constitute medical advice. Always consult your licensed healthcare provider about medication decisions.